IceCure Medical Ltd. (NASDAQ: ICCM) is expanding the US post-market evidence programme for its ProSense breast cryoablation system after West Cancer Center & Research Institute in Germantown, Tennessee received Institutional Review Board approval to begin enrolling patients in the ChoICE study. The study is designed to enroll approximately 400 patients across 30 US sites and examine real-world use of ProSense together with endocrine therapy in women aged 70 years and older who have biologically low-risk breast tumors measuring no more than 1.5 centimeters. Participating centers can also operate as commercial ProSense sites and treat eligible patients outside the study, linking IceCure’s required post-market evidence generation directly with expansion of its US commercial footprint.
The distinction between a post-market study and an investigational pivotal trial matters because ProSense already has FDA marketing authorization. FDA granted De Novo classification to the device on October 3, 2025, creating a Class II category for cryoablation devices used in the local treatment of selected low-risk breast cancers. The authorization covers patients aged 70 and older with biologically low-risk tumors of 1.5 centimeters or less who receive adjuvant endocrine therapy, including certain patients who are not candidates for surgery.
Why did FDA require more evidence after allowing ProSense onto the market?
The clinical evidence supporting ProSense is encouraging but comes primarily from a prospective, single-arm study rather than a randomized comparison with lumpectomy. ICE3 followed patients with small, hormone receptor-positive, HER2-negative invasive breast cancers treated using cryoablation without surgical excision, providing important long-term data but leaving uncertainty about how the procedure compares directly with standard breast-conserving surgery in similar patients. FDA therefore paired market authorization with a post-market surveillance requirement intended to characterize performance in a broader real-world population.
This is an important example of why company and regulatory analyses of the same study can produce different headline numbers. The peer-reviewed ICE3 publication reported a Kaplan-Meier five-year ipsilateral breast tumor recurrence rate of 4.3% among 194 protocol-eligible patients and 3.7% among the subgroup treated with endocrine therapy alone. FDA’s own review used a broader treated population and more conservative recurrence adjudication, producing higher estimates in some analyses, while also identifying a lower-risk subgroup more closely aligned with the eventual authorized indication.
Neither interpretation means the underlying data are contradictory. They reflect different patient sets, recurrence definitions and regulatory assumptions, which is precisely why additional surveillance is valuable after launch. ChoICE should help establish how the authorized population performs when cryoablation moves beyond the original trial centers and into broader clinical practice.
How does ProSense destroy a breast tumor without removing it surgically?
The system uses a thin cryoprobe positioned into the tumor under imaging guidance and circulates liquid nitrogen to produce very low temperatures around the probe tip. Repeated freezing and thawing create an ice ball extending beyond the visible tumor, damaging malignant cells through intracellular ice formation, membrane disruption and vascular injury. The procedure can generally be performed through a small skin entry rather than a surgical incision large enough to remove the tumor physically.
In the ICE3 trial, the device was used under ultrasound guidance and generated a treatment zone around small invasive ductal carcinomas. The peer-reviewed five-year analysis included 194 protocol-eligible patients with a mean age of approximately 75 and average tumor dimensions below one centimeter, illustrating how carefully selected the evidence population was. The five-year estimated ipsilateral recurrence rate was 4.3%, while breast-cancer-specific survival was 96.7%; no serious device-related adverse events were reported in the publication.
Those results cannot be generalized to every breast cancer. Larger tumors, multifocal disease, biologically aggressive subtypes and younger patients have different recurrence risks and may require surgery, radiation, chemotherapy or other treatment strategies. FDA’s authorized population is consequently narrower than the broader phrase “breast cancer cryoablation” might suggest.
Why are women aged 70 and older a particularly important population for treatment de-escalation?
Breast cancer treatment has historically been built around achieving maximal local disease control, but the balance between local treatment intensity and treatment burden changes as patient age, tumor biology and competing health risks change. An older woman with a small, hormone receptor-positive, HER2-negative tumor may have a very different risk profile from a younger patient with aggressive triple-negative disease.
Lumpectomy is highly established and generally safe, but it still requires an operating-room pathway, anesthesia considerations and postoperative recovery. Cryoablation may allow appropriately selected patients to undergo local treatment through a minimally invasive outpatient procedure, potentially reducing recovery time and preserving cosmetic outcomes. In ICE3, the median reported return to normal activity was approximately one day, although procedural convenience must ultimately be weighed against the risk of leaving viable malignant tissue or experiencing later local recurrence.
This is why long-term surveillance matters more than short-term procedural success. A tumor can appear completely encompassed by the ice ball and still recur years later, so a non-surgical strategy needs durable local-control evidence rather than simply demonstrating that patients tolerate the procedure well.
What exactly will the 400-patient ChoICE programme add?
FDA-approved study plans call for approximately 400 patients across 30 clinical sites over about three years, with at least 80 patients expected during the first year under the original programme design. The post-market study focuses on the authorized population and should generate additional real-world information on treatment delivery, safety, local control and use alongside endocrine therapy.
The structure also carries a clear commercial benefit for IceCure. Participating sites can serve simultaneously as study centers and active commercial centers, allowing physicians to develop procedural experience while treating appropriate patients who are not enrolled in the surveillance cohort. This means every additional hospital joining ChoICE can potentially become both an evidence-generation node and a revenue-producing customer for probes and system usage.
West Cancer Center follows other participating institutions, including Adventist Health Glendale, which had already received IRB approval and was positioned to enroll patients earlier in August. The growing site network will matter because the strongest reassurance for physicians may ultimately come from reproducibility across a broad group of surgeons and radiologists rather than another small number of highly experienced investigators.
Could post-market evidence help move breast cryoablation into treatment guidelines?
Regulatory authorization and guideline adoption are separate thresholds. FDA determines whether a device can be marketed for its authorized population based on evidence of safety and effectiveness, while oncology guidelines evaluate how that technology should fit among established alternatives and the strength of comparative evidence supporting routine use.
A recent systematic review found cryoablation technically feasible and generally safe in selected low-risk early-stage breast cancers, but emphasized that comparative evidence remains limited and called for rigorous multicenter studies with long-term follow-up. That limitation is likely to remain central whenever professional societies consider whether cryoablation should sit alongside lumpectomy as routine local treatment rather than remain an option for more narrowly selected patients.
ChoICE cannot retroactively turn ICE3 into a randomized trial, but a 400-patient prospective post-market programme across 30 sites can provide evidence on how well results transfer into routine US practice. IceCure has therefore moved beyond its original regulatory question. ProSense has already crossed the FDA threshold; the next challenge is whether several years of real-world outcomes can persuade enough breast cancer specialists that freezing a carefully selected tumor is not merely less invasive than removing it, but sufficiently predictable to become a durable part of standard care.
